# A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

> **NCT01866007** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 141 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Guselkumab (lyophilized formulation)
- **DRUG:** Guselkumab (liquid formulation with PFS-U)
- **DRUG:** Guselkumab (liquid formulation with PFS FID)
- **DRUG:** Guselkumab (liquid formulation)

## Key facts

- **NCT ID:** NCT01866007
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-09
- **Primary completion:** 2013-09-20
- **Final completion:** 2013-10-09
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866007, "A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01866007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*